Bio-Techne Corporation (TECH)
NASDAQ: TECH · Real-Time Price · USD
53.90
+3.96 (7.93%)
At close: May 12, 2025, 4:00 PM
55.06
+1.16 (2.14%)
After-hours: May 12, 2025, 6:24 PM EDT
Bio-Techne Revenue
Bio-Techne had revenue of $316.18M in the quarter ending March 31, 2025, with 4.20% growth. This brings the company's revenue in the last twelve months to $1.21B, up 4.72% year-over-year. In the fiscal year ending June 30, 2024, Bio-Techne had annual revenue of $1.16B with 1.97% growth.
Revenue (ttm)
$1.21B
Revenue Growth
+4.72%
P/S Ratio
6.53
Revenue / Employee
$396,318
Employees
3,050
Market Cap
8.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 1.16B | 22.36M | 1.97% |
Jun 30, 2023 | 1.14B | 31.10M | 2.81% |
Jun 30, 2022 | 1.11B | 174.57M | 18.75% |
Jun 30, 2021 | 931.03M | 192.34M | 26.04% |
Jun 30, 2020 | 738.69M | 24.69M | 3.46% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TECH News
- 11 hours ago - Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 - PRNewsWire
- 4 days ago - Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing - PRNewsWire
- 4 days ago - Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - PRNewsWire
- 5 days ago - Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Bio-Techne exceeds profit expectations, announces new share buyback plan - Reuters
- 5 days ago - BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM - PRNewsWire
- 5 days ago - BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS - PRNewsWire
- 6 days ago - ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc. - PRNewsWire